儿童急性髓系白血病外周血qPCR检测可测量残留病灶用于疾病监测
该研究对75例儿童AML患者诱导后774份骨髓和外周血样本进行qPCR检测融合基因,发现外周血MRD在巩固后检测阳性或随访中持续/转阳均预测复发,且外周血MRD升至5×10-4以上可定义分子复发。
要点
- 外周血MRD在首次巩固后阳性者8/8复发。
- 随访中外周血MRD持续或转阳者14/14复发。
- 外周血或骨髓MRD增至5×10-4以上可定义为分子复发。
核心结论
- 诱导后外周血MRD监测信息量高,MRD增至5×10-4以上可定义分子复发。
研究设计与样本
- 回顾性分析75例儿童AML患者诱导后774份样本(骨髓347份,外周血427份),采用qPCR检测 recurrent fusion transcripts。
主要发现
- 首次巩固后外周血MRD可检测的8/8患者复发。
- 随访中外周血MRD持续(n=4)或由阴转阳(n=10)预测14/14患者复发。
- 36例持续完全缓解患者的253份随访外周血样本均为MRD阴性。
- 核心结合因子AML中,随访骨髓低水平MRD持续常见,但增至5×10-4以上预示12/12患者后续血液学复发。
关键数值与推荐
- 外周血或骨髓MRD增至5×10-4以上定义为分子复发,因其始终导致血液学复发。
临床怎么用
- 诱导后应监测外周血MRD,首次巩固后阳性或随访中持续/转阳提示高复发风险。
- 外周血或骨髓MRD增至5×10-4以上应考虑分子复发并提前干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Serial assessments of measurable (or minimal) residual disease (MRD) by qPCR may identify nascent relapse in children with acute myeloid leukaemia (AML) and enable pre-emptive therapy. We investigated the kinetics and prognostic impact of recurrent fusion transcripts (RUNX1-RUNX1T1, CBFB-MYH11, KMT2A-MLLT3 or KMT2A-ELL) in 774 post-induction samples from bone marrow (BM, 347) and peripheral blood (PB, 427) from 75 children with AML. BM MRD persistence during consolidation did not increase the risk of relapse, and MRD at therapy completion did not correlate to outcome (HR = 0·64/MRD log reduction (CI: 0·32-1·26), P = 0·19). In contrast, 8/8 patients with detectable MRD in PB after first consolidation relapsed. Persistence (n = 4) and shifting from negative to positive (n = 10) in PB during follow-up predicted relapse in 14/14 patients. All 253 PB samples collected during follow-up from 36 patients in continuous complete remission were MRD negative. In core-binding factor AML, persistent low-level MRD positivity in BM during follow-up was frequent but an increment to above 5 × 10-4 heralded subsequent haematological relapse in 12/12 patients. We demonstrate that MRD monitoring in PB after induction therapy is highly informative and propose an MRD increment above 5 × 10-4 in PB and BM as a definition of molecular relapse since it always leads to haematological relapse.
引用
- Juul-Dam KL, Ommen HB, Nyvold CG, et al. Measurable residual disease assessment by qPCR in peripheral blood is an informative tool for disease surveillance in childhood acute myeloid leukaemia. Br J Haematol. 2020. PMID: 32175599. doi:10.1111/bjh.16560
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。